1. Home
  2. SLN vs VALN Comparison

SLN vs VALN Comparison

Compare SLN & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLN
  • VALN
  • Stock Information
  • Founded
  • SLN 1994
  • VALN 2012
  • Country
  • SLN United Kingdom
  • VALN France
  • Employees
  • SLN N/A
  • VALN N/A
  • Industry
  • SLN Biotechnology: Pharmaceutical Preparations
  • VALN Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • SLN Health Care
  • VALN Health Care
  • Exchange
  • SLN Nasdaq
  • VALN Nasdaq
  • Market Cap
  • SLN 352.2M
  • VALN 345.2M
  • IPO Year
  • SLN N/A
  • VALN 2021
  • Fundamental
  • Price
  • SLN $5.12
  • VALN $4.36
  • Analyst Decision
  • SLN Strong Buy
  • VALN Strong Buy
  • Analyst Count
  • SLN 4
  • VALN 2
  • Target Price
  • SLN $61.50
  • VALN $18.50
  • AVG Volume (30 Days)
  • SLN 460.0K
  • VALN 68.4K
  • Earning Date
  • SLN 03-11-2025
  • VALN 11-07-2024
  • Dividend Yield
  • SLN N/A
  • VALN N/A
  • EPS Growth
  • SLN N/A
  • VALN N/A
  • EPS
  • SLN N/A
  • VALN N/A
  • Revenue
  • SLN $21,773,221.00
  • VALN $176,817,979.00
  • Revenue This Year
  • SLN N/A
  • VALN $24.66
  • Revenue Next Year
  • SLN $104.98
  • VALN $9.67
  • P/E Ratio
  • SLN N/A
  • VALN N/A
  • Revenue Growth
  • SLN N/A
  • VALN N/A
  • 52 Week Low
  • SLN $4.82
  • VALN $3.62
  • 52 Week High
  • SLN $27.72
  • VALN $9.50
  • Technical
  • Relative Strength Index (RSI)
  • SLN 25.52
  • VALN 48.76
  • Support Level
  • SLN $4.82
  • VALN $4.22
  • Resistance Level
  • SLN $7.87
  • VALN $4.51
  • Average True Range (ATR)
  • SLN 0.62
  • VALN 0.21
  • MACD
  • SLN -0.01
  • VALN 0.00
  • Stochastic Oscillator
  • SLN 9.20
  • VALN 41.90

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.

About VALN Valneva SE

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.

Share on Social Networks: